July 26th 2024
Here are the top five articles published on LCGC International this week.
New Method Developed to Detect N-Nitrosamines in Pharmaceuticals
April 19th 2023Sartans are important drugs that help treat hypertension and heart failure. However, since their recall in 2018 because of the presence of genotoxic impurities in these drugs, researchers are tackling the question of how to detect these impurities in these drugs before they go to market. This article describes a HPLC–APCI-MS/MS method that can help in this endeavor.
Purification and Isolation of Cannabinoids: Current Challenges and Perspectives
The current challenges and future perspectives of the purification of cannabinoids from cannabis extracts are presented in this review article.
Building Small But Thinking Big
November 7th 2022The Column spoke to Brett Paull from the University of Tasmania in Hobart, Australia, about the development of truly portable LC systems for use in the pharmaceutical industry and in environmental analysis. Why are they necessary, and where can improvements still be made?
The 2022 Winners of the Lifetime Achievement and Emerging Leader in Chromatography Awards
February 1st 2022Barry L. Karger and James P. Grinias are the winners of the 15th annual LCGC Lifetime Achievement and Emerging Leader in Chromatography Awards, respectively, for 2022. Here, we review their achievements.
Analysis of Boronic Compounds as Potential Mutagenic Impurities in Drug Substances By GC–MS
December 1st 2021This novel gas chromatography (GC)–MS approach enables analysis of the suspected mutagens bis(pinacolato)diboron (BPD) and tetrahydroxydiboron (BBA) found at low-levels in certain intermediates and active pharmaceutical ingredients (APIs), even in the presence of boron from other sources.
Low-Level Determination of Mutagenic Nitrosamine Impurities in Drug Substances by LC–MS/MS
July 12th 2021This article discusses the development of a series of applications that will allow for the determination of a number of nitrosamines that have been identified by the FDA as genotoxins to monitor, initially showing how to perform a separation of these compounds from the API and then looking at how MS can be applied to the analysis to ensure that the required detection limits can be reached.